<DOC>
	<DOCNO>NCT02238353</DOCNO>
	<brief_summary>Comparative analysis efficacy intranasal MP29-02 ( novel formulation azelastine FP ) already conduct patient moderate-to-severe seasonal AR . The combination formulation appear superior patient well symptomatic relief . However , objective analysis effect treatment nasal mediator and/or nasal hyperreactivity yet perform would help understanding additional benefit combination treatment monotherapy nasal corticosteroid .</brief_summary>
	<brief_title>AZELASTINE/FLUTICASONE ( AZE/FLU ) Nasal Spray Symptom Control , Nasal Mediators Nasal Hyperresponsiveness Allergic Rhinitis ( AR )</brief_title>
	<detailed_description>Comparative analysis efficacy intranasal MP29-02 ( novel formulation azelastine FP ) already conduct patient moderate-to-severe seasonal AR . The combination formulation appear superior patient well symptomatic relief . However , objective analysis effect treatment nasal mediator and/or nasal hyperreactivity yet perform would help understanding additional benefit combination treatment monotherapy nasal corticosteroid .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>1 . Patients ARIAbased diagnosis persistent moderate/severe AR ( â‰¥ 2 nasal symptom suggestive allergic rhinitis positive skin prick test house dust mite ( HDM ) ( HAL Allergy , Leiden , The Netherlands ) screening . Patients additional seasonal pollen allergy may include provide included outside individual pollen season , VAS score total nasal symptom 5 2 . VAS TNS 5 , rT5SS 8 screen randomization 3 . Age &gt; 18 &lt; 60 year 4 . Eosinophilia 5 % nasal secretion screen 5 . Nasal hyperreactivity ( drop PNIF &gt; 20 % ) randomization 6 . Possibility give reliable information write informed consent 1 . Any evidence clinically relevant acute chronic cardiovascular , pulmonary , hepatic , renal , gastrointestinal , haematological , endocrine , metabolic , mental , neurological , disease screen 2 . History allergic reaction fluticasone propionate , azelastine hydrochloride one excipients ( e.g . benzalkonium chloride , phenylethyl alcohol , microcrystalline cellulose ) 3 . Patients change vision history increase ocular pressure , glaucoma and/or cataracts 4 . Patients tuberculosis , type untreated infection , recent surgical operation injury nose mouth 5 . Patients prolonged use decongestive nose spray , suffer socalled rhinitis medicamentosa 6 . Patients use nasal oral medication affect nasal function , like nasal corticosteroid , anticholinergic , cromoglycates , leukotriene antagonist , ACE inhibitor study within last 14 day randomization ; patient use oral corticosteroid last 30 day 7 . Patients use cytochrome P450 inhibitor ( e.g . ritonavir ) 8 . Nasal endoscopic evidence rhinosinusitis without nasal polyposis ( NP ) structural abnormality clinically relevant septal deviation ( septum reach concha inferior lateral nasal wall ) septal perforation screen 9 . Patients immunotherapy ( IT ) HDM history IT HDM 10 . Patients psychiatric , addictive , disorder investigator feel may compromise ability give truly informed consent participation study provide reliable information questionnaire 11 . Patients enrol clinical trial within last 3 month 12 . Pregnancy breastfeed 13 . Malignancies severe comorbidity 14 . Smoking 15 . Use anticoagulation medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>